NEW YORK (GenomeWeb News) — The recent debut of consumer genomics services from Decode Genetics and 23andMe have raised questions about whether the US Food and Drug Administration will get involved in regulating the services, and if so, to what extent.
 
An FDA official said this week that while the agency is following these new services with interest, it cannot comment further at this time.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.